The National Comprehensive Cancer Network (NCCN) has published a set of recommendations for the treatment of small bowel adenocarcinoma, representing the first treatment guidelines in the United States for the rare type of cancer.
The National Comprehensive Cancer Network (NCCN) has published a set of recommendations for the treatment of small bowel adenocarcinoma (SBA), representing the first treatment guidelines in the United States for the rare type of cancer.
Adenocarcinomas are the most common type of small bowel cancer, making up approximately 3% of all digestive system cancers and affecting an estimated 10,590 people in 2019. While rates of several gastrointestinal malignancies have dropped in recent years, in part due to increases in screening, rates for small bowel cancers have increased 1.8% between 2006 and 2015. There is a lack of consensus on screening for SBA because it is located higher in the gastrointestinal tract and is thus not detected during a colonoscopy. The disease has been linked with herediatary causes such as Lynch syndrome.
“Historically, small bowel adenocarcinoma has been managed in the same way as colorectal cancer, because SBA is rare and, therefore, difficult to study,” said Katrina Pederson, MD, MS, medical oncologist, Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, and member of the NCCN Guidelines Panel for Colorectal Cancer, in a statement. “The new NCCN Guidelines for Small Bowel Adenocarcinoma were created to reflect new research and biologic insights over the past several years that show optimal SBA management can differ from colorectal cancer treatments.”
The NCCN guidelines place an emphasis on incorporating taxanes—a class of diterpenes—into SBA treatment while straying away from the use of epidermal growth factor receptor inhibitors that do not demonstrate a clear benefit. They also highlight developments in genetic testing.
NCCN also recently updated its NCCN Guidelines for Genetic/Familial Risk Assessment: Colorectal Cancer, which includes a step-by-step process for assessing hereditary colorectal cancer syndromes and places an emphasis on the important of genetic counseling.
“Many of these changes reflect the widespread adoption of multi-gene panel testing for hereditary cancer syndromes, which allows assessment for even rare causes of polyposis and other cancer syndromes,” said Heather Hampel, MS, LGC, professor of Human Genetics, The Ohio State University Comprehensive Cancer Center, and member of the NCCN Guidelines Panel for Genetic/Familial Risk Assessment: Colorectal Cancer, in a statement.
According to Hampel, the updated guidelines include a section on the principles of cancer risk assessment and counseling and refine the initial approach to assessing colorectal cancer syndromes. They also include rare genetic causes for multiple adenomatous polyps and updated criteria for evaluation of Lynch syndrome.
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
January 23rd 2024Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Interventions Needed to Increase DMT Uptake in Sickle Cell Disease
December 26th 2023A recent study found that uptake of disease-modifying therapies (DMTs) has been low among patients with sickle cell disease, suggesting that more interventions that consider individual patient characteristics are needed to improve adoption.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More